Fresenius Medical Care reported third quarter 2026 revenue of €4.94 billion, representing a slight beat against analyst expectations of €4.90 billion. While top-line growth was supported by the large-scale rollout of the 5008X CAREsystem in the U.S. and reimbursement rate increases, bottom-line performance was significantly impacted by strategic refinement costs in China and persistent volume headwinds. Operating income declined 19% year-over-year as the company navigated organizational redesign disruptions that continued to weigh on patient inflow.
Key Highlights
- U.S. Same Market Treatment Growth (SMTG) declined 1.1% in the third quarter, falling below the estimate of -0.9% as organizational changes and clinic footprint optimization impacted referral preferences.
- The FME25+ transformation program achieved €995 million in cumulative sustainable savings since inception, remaining on track for its €1.2 billion goal by year-end 2027.
- A €98 million negative impact was recorded due to the "China Strategy Refinement," which includes exiting the peritoneal dialysis business and discontinuing specific hemodialysis systems in the region.
- The company completed its 2025 share buyback program and initiated a new €1 billion program, repurchasing over 33.9 million shares to date to enhance shareholder value.